cours
system
corticosteroid
may
use
sever
exacerb
patient
chronic
respiratori
failur
requir
longterm
oxygen
treatment
carbon
dioxid
retent
sometim
problem
nasal
intermitt
positivepressur
ventil
effect
case
surprisingli
well
toler
despit
histori
sinus
approach
also
effect
assist
mucu
clearanc
antibiot
given
infect
exacerb
associ
purul
sputum
breathless
malais
choic
antibiot
influenc
like
bacteri
speci
tabl
previou
sputum
cultur
result
presenc
absenc
p
aeruginosa
gener
rule
damag
airway
level
infect
antibiot
dosag
higher
cours
longer
usual
amount
bacteri
resist
also
high
due
previou
antibiot
prescript
eg
blactamas
product
hemophilu
influenza
intraven
antibiot
use
sever
exacerb
resist
speci
oral
antibiot
fail
continu
antibiot
treatment
given
prophylaxi
oral
nebul
rout
regular
plan
cours
intraven
treatment
improv
patient
wellb
probabl
reduc
frequenc
exacerb
number
bacteria
lung
thu
level
inflamm
howev
evid
alter
diseas
progress
definit
risk
drive
lung
flora
toward
resist
strain
speci
p
aeruginosa
stenotrophomona
maltophilia
approach
reserv
patient
despit
optimum
medic
manag
continu
frequent
six
per
year
exacerb
involv
admiss
hospit
great
interest
past
year
macrolid
antibiot
prophylaxi
benefit
thought
due
action
kill
bacteria
via
effect
inflammatori
cell
possibl
mucu
product
sever
studi
provid
encourag
result
promis
area
futur
research
bronchiol
mean
inflamm
bronchiol
clinic
complex
usual
affect
children
less
year
old
character
wheez
dyspnea
tachypnea
poor
feed
clinic
characterist
origin
term
congest
catarrh
fever
recogn
year
late
epidemiolog
viral
etiolog
ill
describ
respiratori
syncyti
viru
rsv
common
caus
bronchiol
amongst
import
pathogen
caus
respiratori
infect
infant
worldwid
epidem
occur
winter
month
temper
climat
raini
season
tropic
climat
figur
us
infant
hospit
annual
rsv
infect
death
attribut
rsv
lower
respiratori
tract
diseas
total
hospit
charg
rsvcode
primari
diagnos
period
estim
us
billion
within
hospit
high
risk
nosocomi
spread
rsv
epidem
put
vulner
infant
risk
sever
diseas
infect
infanc
also
predispos
children
develop
recurr
wheez
thu
increas
longterm
healthcar
burden
diseas
prophylaxi
avail
recombin
monoclon
antibodi
expens
current
limit
infant
highest
risk
sever
diseas
develop
effect
vaccin
would
dramat
effect
morbid
healthcar
cost
unlik
occur
near
futur
treatment
gener
support
infect
run
natur
cours
rsv
primari
caus
bronchiol
seroepidemiolog
studi
show
children
infect
rsv
year
age
infect
spread
droplet
exposur
direct
contact
secret
fomit
infecti
outsid
bodi
h
rsv
first
isol
chimpanze
origin
call
chimpanze
coryza
agent
cca
subsequ
rsv
shown
caus
case
bronchiol
pathogen
known
caus
bronchiol
shown
tabl
histor
case
bronchiol
pathogen
detect
number
report
year
figur
laboratori
report
communic
diseas
surveil
centr
health
protect
agenc
uk
infect
due
respiratori
syncyti
viru
england
wale
wale
reproduc
permiss
hpa
recent
polymeras
chain
reaction
pcr
techniqu
identifi
pathogen
human
metapneumoviru
hmpv
coronaviru
may
gone
undetect
previous
coinfect
hmpv
rsv
may
associ
higher
risk
sever
diseas
rsv
negativesens
singlestrand
rna
pneumoviru
paramyxovirida
famili
figur
viral
genom
contain
gene
encod
viral
protein
nine
structur
protein
glycoprotein
form
viral
coat
bring
attach
host
cell
whilst
two
direct
viral
replic
within
host
cell
tabl
describ
function
protein
base
immunolog
techniqu
two
differ
strain
viru
identifi
b
subsequ
demonstr
two
strain
also
genet
distinct
variabl
strain
due
differ
amino
acid
sequenc
g
protein
viral
coat
strain
seen
commonli
uk
north
america
evid
strain
result
sever
infect
f
protein
respons
fusion
infect
cell
adjac
uninfect
cell
facilit
celltocel
transmiss
viru
result
epitheli
cell
syncytia
appear
appar
larg
multinucl
cell
give
viru
name
rsv
initi
caus
inflamm
bronchiol
destruct
ciliat
epitheli
cell
submucosa
becom
edemat
whilst
cellular
debri
mucu
form
plug
within
bronchiol
neutrophil
alveolar
macrophag
peribronchiolar
infiltr
lymphocyt
associ
edema
fluid
accumul
within
alveoli
sever
diseas
involv
destruct
respiratori
epithelium
parenchym
necrosi
format
hyalin
membran
bronchiolar
epithelium
regener
day
cilia
reappear
day
ill
resolv
spectrum
sever
infect
children
wide
incub
period
day
infant
exhibit
predominantli
upper
respiratori
tract
symptom
includ
rhinorrhea
cough
lowgrad
fever
often
persist
sever
week
resolv
without
symptom
thirti
fifti
percent
infant
progress
develop
lower
respiratori
tract
sign
symptom
within
day
infect
infant
may
develop
rapid
respiratori
rate
wheez
sign
respiratori
distress
subcost
intercost
recess
tracheal
tug
nasal
flare
apnea
present
common
especi
infant
less
week
old
histori
apnea
prematur
congenit
heart
diseas
approxim
infect
children
requir
admiss
hospit
reason
admiss
includ
hypoxia
inadequ
fluid
intak
apnea
sign
immin
respiratori
failur
sever
cough
pharyng
conjunct
otiti
media
may
also
present
irrit
sign
cardiovascular
compromis
lethargi
exhaust
late
sign
may
follow
respiratori
arrest
clinic
intervent
made
one
two
percent
infant
hospit
bronchiol
requir
ventilatori
support
mortal
group
may
prematur
birth
chronic
lung
diseas
prematur
congenit
heart
diseas
cystic
fibrosi
immunodefici
predispos
infant
high
risk
sever
diseas
addit
boy
like
hospit
girl
infant
expos
high
level
particul
air
pollut
cigarett
smoke
also
like
suffer
sever
bronchiol
chest
radiograph
typic
show
hyperinfl
flatten
diaphragm
patchi
peribronchi
infiltr
chest
radiograph
normal
even
sever
case
reduct
oxygen
satur
associ
increas
respiratori
rate
accur
indic
reduc
ga
exchang
seen
sever
diseas
arteri
capillari
blood
ga
analysi
help
assess
chang
clinic
statu
particularli
ventilatori
support
consid
infant
given
adequ
support
care
improv
clinic
day
within
week
height
ill
infant
normal
respiratori
rate
radiolog
abnorm
clear
howev
infant
may
suffer
persist
wheez
airway
obstruct
sever
month
especi
requir
hospit
admiss
longer
term
airway
reactiv
increas
children
infect
persist
least
year
still
uncertain
whether
rsv
caus
asthma
later
life
rsv
infect
confer
last
immun
reinfect
howev
subsequ
infect
usual
less
sever
like
limit
upper
respiratori
tract
rsv
first
infect
ciliat
epitheli
cell
respiratori
tract
subsequ
diseas
manifest
caus
combin
viral
cytotox
immun
respons
infect
effect
summar
figur
contact
epitheli
cell
g
protein
attach
viru
epitheli
cell
allow
viral
rna
enzym
enter
cell
initi
product
new
viral
rna
protein
f
protein
mediat
format
syncytia
enabl
viru
spread
rapidli
multipl
new
virus
assembl
within
cell
ultim
destroy
lead
slough
epithelium
cell
destroy
releas
proinflammatori
substanc
cytokin
increas
capillari
permeabl
attract
inflammatori
cell
neutrophil
secret
macrophag
eosinophil
rant
natur
killer
cell
interferon
ifn
ab
secret
mediat
stimul
mucu
product
whilst
other
leukotrien
caus
bronchoconstrict
pulmonari
surfact
function
also
inhibit
increas
product
impair
clearanc
cellular
debri
mucu
result
plug
small
airway
air
trap
atelectasi
infant
preexist
poor
lung
function
chronic
lung
diseas
airway
obstruct
like
clinic
signific
caus
sever
diseas
immun
respons
rsv
includ
innat
adapt
compon
innat
immun
respons
recogn
import
previous
thought
capabl
influenc
subsequ
adapt
immun
respons
innat
immun
import
defens
rsv
virus
caus
bronchiol
adapt
immun
respons
infant
rel
immatur
innat
immun
respons
rapid
recruit
effector
molecul
phagocyt
cell
site
infect
releas
cytokin
pulmonari
surfact
provid
earli
defens
viral
infect
surfact
protein
member
collectin
famili
bind
surfac
number
pathogen
includ
rsv
viru
thu
opson
capabl
bind
complement
receptor
phagocyt
cell
neutrophil
macrophag
eosinophil
natur
killer
cell
tolllik
receptor
tlr
import
receptor
present
epitheli
cell
phagocyt
cell
recogn
distinct
nonhuman
pathogenassoci
molecular
pattern
pamp
although
precis
role
still
elucid
tlr
import
receptor
innat
adapt
immun
respons
rsv
receptor
surfact
protein
bind
rsv
shown
coreceptor
figur
pathogenesi
rsv
bronchiol
rsv
first
infect
ciliat
epitheli
cell
respiratori
tract
inflammatori
cytokin
chemokin
secret
infect
epitheli
cell
macrophag
attract
inflammatori
cell
caus
inflamm
bronchoconstrict
airway
predomin
inflammatori
cell
airway
neutrophil
alveolar
macrophag
dendrit
cell
main
antigenpres
cell
stimul
tlymphocyt
function
neutrophil
surviv
prolong
secret
promot
mucu
product
thelper
lymphocyt
may
skew
produc
proinflammatori
cytokin
combin
epitheli
cell
slough
mucu
plug
airway
inflamm
lead
clinic
present
acut
bronchiol
gene
associ
risk
sever
diseas
recogn
doublestrand
rna
endosom
cell
initi
immun
respons
rsv
pulmonari
dendrit
cell
also
express
tlr
predomin
antigenpres
cell
rsv
infect
circul
dendrit
cell
recruit
site
viral
replic
lung
produc
larg
amount
type
interferon
ifna
b
stimul
subsequ
tlymphocyt
respons
rsv
infect
regulatori
lymphocyt
reg
known
dampen
inflammatori
respons
could
stimul
rsv
either
via
tlr
express
cell
surfac
via
pulmonari
dendrit
cell
therefor
provid
way
tlymphocyt
respons
rsv
influenc
innat
adapt
immun
alveolar
macrophag
phagocyt
function
act
mainli
antigenpres
cell
interact
helper
cytotox
lymphocyt
along
respiratori
epitheli
cell
respond
via
tlr
signal
pathway
secret
cytokin
increas
tissu
permeabl
well
attract
activ
addit
inflammatori
cell
neutrophil
predomin
airway
leukocyt
rsv
bronchiol
repres
cell
upper
airway
cell
lower
airway
neutrophil
chemotaxi
depend
product
potent
chemotract
airway
epitheli
cell
macrophag
secret
soon
infect
lead
almost
immedi
inflammatori
respons
infect
establish
later
peak
secret
depend
viral
replic
genet
polymorph
gene
associ
risk
sever
diseas
neutrophil
recruit
adher
epitheli
cell
increas
persist
rsv
infect
neutrophil
whose
surviv
prolong
secret
product
myeloperoxidas
neutrophil
elastas
amplifi
viral
cytotox
neutrophil
also
shown
secret
larg
quantiti
lung
sever
infect
infant
potent
proinflammatori
cytokin
known
caus
eosinophil
inflamm
bronchial
hyperrespons
increas
mucu
product
neutrophil
function
therefor
play
import
role
patholog
chang
occur
bronchiol
eosinophil
might
expect
import
role
pathogenesi
bronchiol
antivir
activ
eosinophil
chemoattract
secret
infect
respiratori
epitheli
cell
follow
clinic
trial
formalininactiv
vaccin
postmortem
examin
reveal
massiv
eosinophil
infiltr
howev
subsequ
clinic
studi
report
signific
number
eosinophil
airway
infant
rsv
bronchiol
adapt
immun
rsv
gener
compos
protect
humor
immun
b
cell
antibodi
viral
clearanc
cell
humor
respons
rsv
infect
result
product
igg
igm
iga
antibodi
blood
airway
secret
protect
benefit
antibodi
demonstr
reduc
likelihood
infect
first
month
life
term
babi
due
carriag
matern
igg
antibodi
prophylaxi
monoclon
antirsv
igg
palivizumab
shown
reduc
incid
frequenc
infect
highrisk
infant
also
demonstr
role
humor
respons
evid
anim
model
confirm
antibodi
protect
rsv
diseas
infect
establish
tcell
respons
promot
viral
clearanc
role
cellmedi
immun
demonstr
children
defici
cellular
immun
shed
viru
mani
month
initi
infect
compar
week
immunocompet
infant
cellmedi
respons
compos
cytotox
lymphocyt
thelper
lymphocyt
cytotox
lymphocyt
import
recoveri
pathogenesi
rsv
bronchiol
promot
clearanc
rsv
lung
also
caus
pulmonari
injuri
function
studi
tlymphocytedeplet
mice
demonstr
prolong
rsv
replic
yet
overt
evid
ill
thelper
cell
tradit
subdivid
accord
cytokin
profil
secret
cell
produc
interferon
gamma
ifng
antivir
cytokin
cell
produc
cytokin
induc
eosinophil
prolifer
releas
leukotrien
ige
antibodi
lead
enhanc
inflammatori
respons
idea
rsv
bronchiol
might
diseas
may
explain
airway
obstruct
postbronchiolit
wheez
somewhat
limit
evid
support
multipl
factor
like
influenc
tlymphocyt
respons
rsv
infect
sever
experiment
anim
model
use
improv
understand
pathophysiolog
rsv
bronchiol
varieti
anim
model
use
reflect
divers
clinic
manifest
rsv
diseas
depend
individu
age
genotyp
phenotyp
immun
statu
concurr
diseas
rsv
shown
replic
anim
model
primat
cotton
rat
mice
calv
guinea
pig
ferret
hamster
use
need
investig
immunolog
respons
rsv
use
good
anim
model
highlight
unsuccess
develop
first
formalininactiv
fi
rsv
vaccin
natur
rsv
infect
occur
children
given
vaccin
children
hospit
two
children
die
interpret
trial
result
hamper
lack
small
anim
model
vaccineenhanc
diseas
could
studi
appar
vaccin
formul
also
capabl
stimul
inappropri
immun
respons
rsv
therefor
comprehens
studi
use
anim
model
essenti
human
vaccin
trial
undertaken
key
understand
pathogenesi
bronchiol
cotton
rat
prove
use
anim
model
uniformli
suscept
pulmonari
infect
adulthood
immunolog
respons
mice
rsv
studi
use
cotton
rat
model
larg
respons
develop
rsvneutral
igg
prevent
pulmonari
infect
treatment
ribavarin
despit
cotton
rat
congen
transgen
knockout
strain
limit
avail
reagent
use
character
immunolog
respons
rsv
mice
wide
use
model
due
wide
array
inbr
congen
transgen
knockout
strain
also
reagent
avail
specif
rsv
immunolog
rel
low
mainten
cost
mani
insight
gain
immun
respons
rsv
could
achiev
use
model
balbc
mous
particularli
import
develop
similar
airway
inflammatori
respons
human
intranas
rsv
infect
mice
studi
use
investig
immunolog
rsv
infect
especi
cytokin
respons
viru
experiment
vaccin
admiss
hospit
infant
monitor
assess
regularli
puls
oximetri
fluid
balanc
respiratori
rate
use
assess
chang
infant
condit
barrier
nurs
stringent
handwash
polici
shown
reduc
nosocomi
spread
rsv
rapid
rsv
antigen
test
either
immunofluoresc
enzym
immunoassay
nasopharyng
secret
use
determin
rsv
statu
hospit
despit
consider
effort
develop
effect
treatment
rsv
bronchiol
effect
measur
exist
support
care
cornerston
support
care
supplement
oxygen
correct
hypoxia
adequ
fluid
administr
infant
inadequ
fluid
intak
may
need
nasogastr
feed
unsuccess
intraven
fluid
intraven
fluid
given
care
due
possibl
worsen
lung
fluid
accumul
left
ventricular
overload
larg
number
trial
metaanalys
investig
efficaci
b
agonist
ipratropium
patient
bronchiol
compel
evid
bronchodil
use
treatment
bronchiol
may
subgroup
patient
bronchodil
safe
efficaci
howev
criteria
exist
identifi
subgroup
signific
number
studi
found
patient
deterior
receiv
bronchodil
inconsist
result
explain
knowledg
caus
wheez
bronchiol
bronchodil
effect
increas
mucu
product
slough
epitheli
cell
airway
interstiti
edema
ribavarin
antivir
prepar
administ
aerosol
design
inhibit
synthesi
viral
structur
protein
although
earli
trial
ribavarin
support
use
later
trial
found
signific
posit
effect
addit
potenti
teratogen
labor
intens
administ
treatment
fail
demonstr
consist
benefit
treatment
bronchiol
includ
epinephrin
inhal
system
corticosteroid
recombin
human
dnase
interferona
vitamin
antibiot
two
immunoprophylact
agent
current
avail
recommend
infant
risk
sever
infect
rsv
immun
globulin
intraven
rsvigiv
polyclon
hyperimmun
globulin
prepar
donor
select
high
serum
titer
rsv
neutral
antibodi
palivizumab
human
murin
monoclon
igg
antibodi
rsv
fglycoprotein
given
monthli
intramuscular
inject
rsv
season
rsvigiv
first
immunoprophylact
agent
licens
prevent
sever
rsv
bronchiol
clinic
trial
demonstr
reduct
hospit
admiss
attribut
rsv
lower
respiratori
tract
infect
howev
rsvigiv
number
disadvantag
result
declin
use
favor
palivizumab
earli
trial
report
increas
postop
mortal
patient
cyanot
congenit
heart
diseas
receiv
rsvigiv
administr
requir
intraven
access
infus
everi
month
concern
regard
volum
overload
interfer
live
vaccin
theoret
risk
infect
human
donor
trial
palivizumab
also
demonstr
benefit
highrisk
infant
earli
trial
demonstr
reduct
hospit
admiss
attribut
rsv
lower
respiratori
tract
infect
free
potenti
risk
infect
human
donor
interfer
immun
respons
vaccin
administ
easili
without
need
hospit
admiss
clinic
trial
also
demonstr
safeti
infant
hemodynam
signific
congenit
heart
diseas
howev
trial
demonstr
signific
reduct
mortal
due
rsv
infect
although
palivizumab
shown
reduc
rate
hospit
intens
care
admiss
larg
doubleblind
random
control
trial
sever
studi
question
costeffect
american
academi
pediatr
recommend
use
certain
highrisk
group
children
year
chronic
lung
diseas
requir
medic
therapi
infant
born
week
gestat
first
year
life
infant
born
week
gestat
month
age
infant
born
week
gestat
lower
risk
hospit
palivizumab
recommend
infant
two
risk
factor
child
care
attend
school
age
sibl
parent
smoke
congenit
abnorm
airway
infant
hemodynam
signific
congenit
heart
diseas
also
like
benefit
palivizumab
recommend
group
particularli
cyanot
heart
diseas
congest
heart
failur
pulmonari
hypertens
littl
knowledg
regard
benefit
immunocompromis
infant
children
cystic
fibrosi
prophylaxi
second
year
life
